Soleno Therapeutics Faces Legal Scrutiny Following Patient Incident

Soleno Therapeutics finds itself navigating turbulent waters after reports emerged of a patient fatality connected to its lead drug candidate, VYCAKT XR. The situation has intensified with multiple prominent law firms announcing investigations into whether the biopharmaceutical company may have made misleading statements to its investors. This development raises critical questions about the company’s future trajectory and the commercial viability of its flagship treatment.

The immediate catalyst for the current volatility was the disclosure involving a 17-year-old patient who passed away while undergoing treatment with VYCAKT XR. Soleno Therapeutics promptly issued a statement noting that the attending physician had found no causal link to the medication. Despite this clarification, investor sentiment soured dramatically, triggering a sharp sell-off that erased over... Read more...